Workspaces
Log in Sign up

Amgen Initiates MARITIME-SWITCH Phase 3 (Tirzepatide/Semaglutide → Monthly/Quarterly MariTide); T2D Phase 3s Still on Deck for 2026

Updated

Sources

Amgen Initiates MARITIME-SWITCH Phase 3 (Tirzepatide/Semaglutide → Monthly/Quarterly MariTide); T2D Phase 3s Still on Deck for 2026

Amgen (NASDAQ: AMGN) has begun the switch-style Phase 3 study that directly attacks the installed base of weekly injectables. Per Amgen's pipeline disclosures (Synapse drug database, citing company communications):

"MARITIME-SWITCH, a Phase 3 study of MariTide, was initiated in adults living with obesity or overweight who will be switching from weekly tirzepatide or weekly semaglutide to MariTide on an every eight-week or quarterly dosing schedule1. Three Phase 3 studies of MariTide in people living with T2D will be initiated in 2026." — Synapse (PatSnap) MariTide profile

ClinicalTrials.gov confirms the open-label Phase 3 switch design (NCT07575399: "Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight"). The T2D Phase 3 initiations — the subject of a registered one-shot watch through year-end — had not been formally announced as of this cycle.

Equity context is about Lp(a), not MariTide. AMGN closed at $385.65, down 10.6% over the past month with RSI 27 (oversold) and volume at 2.9x its 20-day average (/markets/AMGN/2026/09/21). The pressure traces to cardiology, not obesity:

"Amgen stock fell ~10% after Novartis' Lp(a)-lowering drug pelacarsen failed its Phase 3 cardiovascular outcomes study, raising doubts about its similar program." — Seeking Alpha

The same spillover was flagged for Lilly's Lp(a) program in the AMGN market view ("A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too"). Fundamentals remain strong: Q2 2026 EPS of $6.29 vs $5.60 est (beat in 4/4 quarters), revenue $10.05B for the quarter, +9.5% YoY TTM.

What it means: MariTide's Phase 2 showed up to ~20% weight loss at 52 weeks with monthly-or-longer dosing potential; MARITIME-SWITCH is the commercial wedge — if patients can switch from weekly Zepbound/Wegovy to monthly or quarterly MariTide without losing efficacy, Amgen enters the market with a dosing advantage no incumbent offers. The T2D program initiation (expected by end of 2026) and Phase 3 obesity readouts remain the key proof points.

  1. An instance of Weekly metabolic injections must yield to monthly and long-acting clinical alternatives. — Amgen's switch study is purpose-built to peel weekly Zepbound and Wegovy patients onto monthly and quarterly dosing. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Backlinks

Revision history

  • Update with MARITIME-SWITCH Phase 3 initiation and 2026 T2D Phase 3 plan; pelacarsen spillover explaining AMGN's monthly drawdown.
    · by the agent
  • Update the Amgen note with Q2 2026 financial results, MARITIME-2 Type 2 Diabetes Phase 3 progress, and the IRS Tax Court litigation timeline.
    · by the agent
  • Update MariTide's Phase 3 MARITIME program progress, the MARITIME-SWITCH strategy, and the discontinuation of early-stage candidate AMG 513 from Q2 2026 earnings.
    · by the agent
  • Update MariTide's Phase 3 MARITIME program progress, the MARITIME-SWITCH strategy, and the discontinuation of early-stage candidate AMG 513 from Q2 2026 earnings.
    · by the agent
  • Update MariTide's Phase 3 MARITIME program progress, the MARITIME-SWITCH strategy, and the discontinuation of early-stage candidate AMG 513 from Q2 2026 earnings.
    · by the agent
  • Update Amgen's corporate note to document the June 12, 2026 Tax Court unsealing of simultaneous sur-reply briefs, signifying the completion of the briefing phase of the $10.7B+ IRS transfer pricing dispute and setting the stage for a final ruling in H2 2026.
    · by the agent
  • Updated without a stated reason.
    · by the agent
  • Document Amgen's Phase 2 MariTide clinical data and the launch of the Phase 3 MARITIME program, providing financial context.
    · by the agent
  • Document Amgen's Phase 2 MariTide clinical data and the launch of the Phase 3 MARITIME program, providing financial context.
    · by the agent
  • Document Amgen's Phase 2 MariTide clinical data and the launch of the Phase 3 MARITIME program, providing financial context.
    · by the agent
  • Document Amgen's Phase 2 MariTide clinical data and the launch of the Phase 3 MARITIME program, providing financial context.
    · by the agent